The cancer biopsy market size in the major markets was valued at USD 28.7 billion in 2023, driven by the incidence of cancer cases across the 7 major markets. The market is expected to grow at a CAGR of 13.2% during the forecast period of 2024-2032, with the values likely to rise from USD 32.5 billion in 2024 to USD 87.4 billion by 2032.
Cancer Biopsy is a type of diagnostic method to detect the presence of a tumour in a body part. It is done by removing a piece of tissue or a sample of cells from the body to test externally in a lab. If cancer exists, a biopsy can help in the determination of its grade. Doctors mostly prescribe it if a patient shows underlying signs of cancer like weakness or fatigue.
After taking the tissue sample, it is sent to a laboratory where it can be chemically treated or frozen and sliced into thin sections. These sections are later placed on glass slides and studied under a microscope. There are different types of biopsies like needle biopsies, skin biopsies, endoscopic biopsies, and others.
Cancer is one of the most fatal diseases, affecting a substantial portion of the population. As there has been significant emphasis on treatment, early diagnosis plays a critical role in decreasing the number of mortalities related to it. Therefore, the cancer biopsy market demand has increased over the years.
Over the years, liquid biopsy has been a preferred method of detection when compared to conventional technology. This can be attributed to its safe, non-invasive, and easily recurring process. With a vision to expand the potential of liquid biopsy to detect and monitor cancer, researchers at the AACR annual meeting 2023 presented a study of an MCED test which utilizes a new platform to analyze DNA methylation. This new platform captures methylated cfDNA without any prior chemical treatment, which leads to easy distinguishing between cancer and non-cancer cells with high precision.
Researchers at Breast Cancer Research Foundation also developed HDSCA 3.0, the novel third-generation liquid biopsy technology, that uses five distinct biomarkers to identify and detect rare circulating cells. In addition, early-stage lung cancer detection has also observed significant advancements. For example, Biomark’s blood based metabolomic biomarker panel got clinically approved by the FDA in June 2023. The cancer biopsy market growth is certain, owing to the holistic research in developing better diagnostic solutions in cancer.
Market Breakup by Product and Services
Market Breakup by Type
Market Breakup by Region
Cancer is the second most prevalent chronic illness after cardiovascular diseases in the United States, as a result, it has dominated the cancer biopsy market share in the historical period. The presence of key medical industry pioneers along with a robust infrastructure and relevant awareness on diagnostics has contributed to the market share.
During the forecast period, EU-4 is anticipated to lead the major markets as there are some major developments occurring in the region. For instance, Hungary has become a hub of artificial intelligence led technologies to detect cancer at an early stage, which is set to revolutionize the entire diagnostic market. Moreover, the Welsh government launched a new diagnostic strategy in Wales to lower the burden of lung cancer in the region.
Asia Pacific, especially Japan, is expected to witness the fastest growth which can be accredited to an intense emphasis on providing relevant awareness to the people to prevent cancer cases. Hence, the cancer biopsy market size will expand. In addition, there are several research and development initiatives to drive contemporary innovations in the field, aiding growth in upcoming years.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product and Services||
|Breakup by Type||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Cancer Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Cancer Epidemiology Forecast (2017-2032)
5.3.1 Germany Cancer Epidemiology Forecast (2017-2032)
5.3.2 France Cancer Epidemiology Forecast (2017-2032)
5.3.3 Italy Cancer Epidemiology Forecast (2017-2032)
5.3.4 Spain Cancer Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Cancer Epidemiology Forecast (2017-2032)
5.4 Japan Cancer Epidemiology Forecast (2017-2032)
6 Cancer Biopsy Market Overview – 7MM
6.1 Cancer Biopsy Market Historical Value (2017-2023)
6.2 Cancer Biopsy Market Forecast Value (2024-2032)
7 Cancer Biopsy Market Landscape – 7MM
7.1 Cancer Biopsy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cancer Biopsy Product Landscape
7.2.1 Analysis by Product & Services
7.2.2 Analysis by Type
8 Cancer Biopsy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cancer Biopsy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cancer Biopsy Market Segmentation – 7MM
11.1 Cancer Biopsy Market by Product and Services
11.1.1 Market Overview
11.1.2 Kits and Consumables
11.2 Cancer Biopsy Market by Type
11.2.1 Market Overview
11.2.2 Needle Biopsy
11.2.3 Skin Biopsies
11.2.4 Bone Marrow Biopsies
11.2.5 Liquid Biopsies
11.2.6 Other Biopsies
11.3 Cancer Biopsy Market by Region
11.3.1 Market Overview
11.3.2 United States
11.3.3 EU-4 and the United Kingdom
188.8.131.52 United Kingdom
12 United States Cancer Biopsy Market
12.1 Cancer Biopsy Market Historical Value (2017-2023)
12.2 Cancer Biopsy Market Forecast Value (2024-2032)
12.3 Cancer Biopsy Market by Type
12.4 Cancer Biopsy Market by Treatment Type
13 EU-4 and United Kingdom Cancer Biopsy Market
13.1 Cancer Biopsy Market Historical Value (2017-2023)
13.2 Cancer Biopsy Market Forecast Value (2024-2032)
13.3 Germany Cancer Biopsy Market Overview
13.3.1 Cancer Biopsy Market by Type
13.3.2 Cancer Biopsy Market by Treatment Type
13.4 France Cancer Biopsy Market Overview
13.4.1 Cancer Biopsy Market by Type
13.4.2 Cancer Biopsy Market by Treatment Type
13.5 Italy Cancer Biopsy Market Overview
13.5.1 Cancer Biopsy Market by Type
13.5.2 Cancer Biopsy Market by Treatment Type
13.6 Spain Cancer Biopsy Market Overview
13.6.1 Cancer Biopsy Market by Type
13.6.2 Cancer Biopsy Market by Treatment Type
13.7 United Kingdom Cancer Biopsy Market Overview
13.7.1 Cancer Biopsy Market by Type
13.7.2 Cancer Biopsy Market by Treatment Type
14 Japan Cancer Biopsy Market
14.1 Cancer Biopsy Market Historical Value (2017-2023)
14.2 Cancer Biopsy Market Forecast Value (2024-2032)
14.3 Cancer Biopsy Market by Type
14.4 Cancer Biopsy Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnerships and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.2 Illumina, Inc.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.3 ANGLE plc
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.4 BD (Becton, Dickinson and Company)
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.5 Bio-Rad Laboratories Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.6 Hologic, Inc.
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.7 BIOCEPT, INC.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.8 Thermo Fisher Scientific, Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.9 F. Hoffmann-La Roche Ltd.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
21 Cancer Biopsy Market- Distribution Model (Additional Insight)
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 28.7 billion in 2023, driven by the rising prevalence of cancer.
The market is anticipated to grow at a CAGR of 13.2% during the forecast period of 2024-2032, likely to reach a market value of USD 87.4 billion by 2032.
The prevalence of cancer has led to significant technical advances in the diagnostic methods with a motive to decrease the number of deaths associated with it. Hence, market demand has increased.
Liquid biopsy is facing some major developments in the market. For example, HDSCA 3.0 is the latest third generation liquid biopsy technique that has emerged in the market. Other vital technology is the MCED test. Europe is expected to lead the market in the forecast period, which is a result of several ground-breaking research in the area. Hungary is a hub for artificial intelligence led diagnostics.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
Technologies include tissue biopsies, liquid biopsies, needle biopsy, skin biopsies, and bone marrow biopsies, among others.
It includes kits and consumables, instruments, and services.
Key players involved in the market are QIAGEN, Illumina, Inc., ANGLE plc, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Hologic, Inc., BIOCEPT, INC., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., and Danaher.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.